9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin

First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin

Estimated reading time: < 1 min

Condition: Advanced Recurrent Epithelioid Mesothelioma or Serous Ovarian Cancer

Estimated Enrollment: 228

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Incidence of DLTs (dose-limiting toxicity),  Cmax of Thorium-227 after single dose of Cycle 1,  Cmax of Radium-223 after single dose of Cycle 1, Cmax of Total antibody after single dose of Cycle 1

Interventions: BAY2287411, BAY2287411

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Sequential Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: June 6, 2022

Completion Date: February 20, 2023

Last  Posted Date: July 26, 2019

Location: National Cancer Institute, Bethesda, Maryland, United States

Website Link: https://ClinicalTrials.gov/show/NCT03507452

Was this article helpful?
Dislike 0